96413-13-7
Chemical Structure
Perrimustine
- CAS No.: 96413-13-7
- Formula:C6H12ClN3O3S
- Molecular Weight:241.70
IUPAC Name: 1-(2-chloroethyl)-3-(2-(methylsulfinyl)ethyl)-1-nitrosourea
InChIKey: QRFYQIBEORUKDP-UHFFFAOYSA-N
SMILES: CS(CCNC(N(N=O)CCCl)=O)=O
Biological Activity: Perrimustine is a cysteamine (CysA) derivative with potent antitumor activity. Perrimustine exhibits significant effect on B16 melanoma and metastasized melanoma cells by causing DNA damage. Perrimustine exhibits antitumor effects in mice bearing various cancers, including lung carcinoma, leukemia, lymphoma, melanoma, colon carcinoma, and glioma. Perrimustine can be used for cancer research, such as melanoma and leukemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Perrimustine | Perrimustine is a cysteamine (CysA) derivative with potent antitumor activity. Perrimustine exhibits significant effect on B16 melanoma and metastasized melanoma cells by causing DNA damage. Perrimustine exhibits antitumor effects in mice bearing various cancers, including lung carcinoma, leukemia, lymphoma, melanoma, colon carcinoma, and glioma. Perrimustine can be used for cancer research, such as melanoma and leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Kim-Triana B, et al. Phase I trial of Perrimustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme. Anticancer Drugs. 1992 Jun;3(3):225-31. [Content Brief]
- [2]. Godeneche D, et al. DNA damage induced by a new 2-chloroethyl nitrosourea on malignant melanoma cells. Cancer Res. 1990 Sep 15;50(18):5898-903. [Content Brief]
Keywords
